WeForNews | Latest News, Breaking News, News Updates Young adults more likely to die from epilepsy: Study | WeForNews | Latest News, Blogs
Connect with us

Health

Young adults more likely to die from epilepsy: Study

Published

on

Brain.

London : A new study has claimed that young adults aged between 16 and 24 may have a six-fold increased risk of epilepsy-related death, a disorder in which nerve cell activity in the brain is disturbed, causing seizures.

The study, presented at the European Academy of Neurology (EAN) Virtual Congress, found that mortality rates for epilepsy-related deaths did not decrease between 2009 (6.8 per 100,000) and 2015 (9.1 per 100,000), despite advances in treatment during this time.

Young adult patients in their early 20s and 30s were found to be at the highest risk, with 78 per cent of epilepsy-related deaths under the age of 55 years classified as potentially avoidable.

The study, being conducted in Scotland, aims identify the burden of epilepsy-related deaths, what proportion of these are potentially avoidable, and ascertain the factors that may put patients at an increased risk.

“Epilepsy patients are at a higher risk of early death than the general population, but reasons for this are unclear,” said study researcher Gashirai Mbizvo from the University of Edinburgh in Scotland.

“We hope that we can use this data to learn lessons and reduce the burden of epilepsy-related deaths in the future, many of which we believe are likely to be avoidable,” Mbizvo added.

Epilepsy is a chronic noncommunicable disease of the brain that affects around 50 million people globally, making it one of the most common neurological diseases worldwide.

For the findings, the researchers collected anonymous data from healthcare settings for patients that died between 2009 and 2016, identifying 2,149 epilepsy-related deaths.

At least 60 per cent of these patients (1,276) had one or more seizure-related or epilepsy-related hospital admission in the years prior to death, yet less than a quarter (516) were seen in a neurology clinic.

The most common causes of death within the study were sudden unexpected death in epilepsy (SUDEP), aspiration pneumonia, cardiac arrest, congenital malformation and alcohol-related deaths.

The data will be compared with data from living patients with epilepsy of the same age and gender.

“Highlighting such risk factors, and identifying those that could be prevented, might lead to changes in epilepsy care and, ultimately, fewer epilepsy-related deaths in the future,” the researchers noted.

Health

Congress alleges govt procuring Covid vaccine at inflated prices

The Congress leader said the price of such a vaccine must be cheaper than AstraZeneca-Serum Institute of India’s Covishield.

Published

on

By

Covid 19 Vaccine

New Delhi, Jan 17 : The Congress on Sunday questioned the procurement of Covid vaccines, alleging that the government has procured the vaccines at inflated prices despite the manufacturers claiming they would supply the vaccines without seeking profit.

Congress General Secretary Randeep Singh Surjewala, addressing a press conference, said, “Why should the Modi government pay Rs 95 per dose more to Bharat Biotech for a vaccine that has been developed with the expertise and experience of scientists of government-run ICMR and pay more for a vaccine that has only been tested on 755 individuals and is yet to be cleared after phase-3 trials?”

The Congress leader said the price of such a vaccine must be cheaper than AstraZeneca-Serum Institute of India’s Covishield.

“Why is the price of the vaccine at Rs 1,000 per dose in the open market?” he asked.

Surjewala said, “‘Covishield’ is an AstraZeneca vaccine manufactured by Serum Institute of India. Serum Institute is supplying this vaccine at Rs 200/dose to government. AstraZeneca has committed to supplying the vaccine at no profit while ‘Covaxin’, manufactured by Bharat Biotech, is being supplied at Rs 295/dose. Admittedly, Covaxin has been developed by Bharat Biotech in partnership with Indian Council of Medical Research (ICMR).”

SII CEO Adar Poonawalla had said stated that his company will sell Covishield for Rs 1,000 per dose in open market, that is Rs 2,000 for 2 doses required for every individual.

Surjewala said, “Why should export of vaccine be permitted without immunisation of India’s population? ‘Corona Vaccine For All’ should be the stated policy of Modi government.”

“However, the government’s approach on free vaccination or cost of vaccination, cost to exchequer, profit margins of companies, etc, for India’s 130 crore people is completely opaque and shrouded in secrecy,” he said.

Continue Reading

Health

13 Israelis suffer facial paralysis post inoculation

“For at least 28 hours, I walked around with it (facial paralysis),” one person who had the side effect told Ynet.

Published

on

By

Vaccine

Jerusalem, Jan 17 : At least 13 Israelis suffered mild facial paralysis as a side effect after receiving the first Covid vaccine jabs, the Health Ministry said, adding that the count could be higher.

The officials have raised questions on whether or not to administer the second dose to these individuals the Health Ministry had recommended for the second dose, reported the Jerusalem Post.

“For at least 28 hours, I walked around with it (facial paralysis),” one person who had the side effect told Ynet.

“I can’t say it was completely gone afterwards, but other than that I had no other pains, except a minor pain where the injection was, but there was nothing beyond that.”

As for receiving the second dose, he admits he is undecided, but says that “it is important to note that this is something rare, and I don’t want people to avoid getting vaccinated – it’s important”.

“I recently came across, for example, someone vaccinated who was dealing with paralysis, and decided not to give her a second dose,” Galia Rahav, Director of the Infectious Diseases Unit at Sheba Medical Centre told Ynet.

“It is true that it can be given according to the Health Ministry, but I did not feel comfortable with it.”

She added that, “No one knows if this is connected to the vaccine or not. That’s why I would refrain from giving a second dose to someone who suffered from paralysis after the first dose.”

However, the Health Ministry has assured of the second dose only when the paralysis passes, Ynet reported.

Continue Reading

Cities

Delhi reports 51 cases of minor adverse events post vaccination

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Published

on

By

Covid 19 Vaccine

Hours after the Health Ministry announced on January 16 that India has reported no case of post-vaccination hospitalisation yet, 51 persons complained of minor adverse events in Delhi. Another person developed severe adverse event following immunization and had to be referred to the AEFI centre.

Out of a total of 4,319 healthcare and frontline workers who were vaccinated on Jnauary 16 in the National Capital, two healthcare workers at NDMC’s Charak Palika Hospital reported mild adverse event post-vaccination including mild tightness in the chest. They were kept under observation by AEFI team and discharged 30 minutes later after they felt at ease. The two other cases were reported from Northern Railway Central Hospital, of which one was referred to the AEFI centre, the Delhi government has informed.

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Beneficiaries from 11 states and union territories across India received Covishield or Covaxin shots on the first day of the vaccination drive, namely, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Telangana, and Uttar Pradesh.

Follow our coverage of the coronavirus crisis here

Continue Reading
Advertisement

Most Popular